



ASX RELEASE (16 SEPTEMBER 2022)

## Capital Raising

Epsilon Healthcare Limited (ASX:EPN) (Epsilon or the Company) advises that on 9 September 2022 it issued a total of 56,363,639 Fully Paid Ordinary Shares (the Securities) without disclosure to the recipients under recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the Corporations Act).

The Company hereby gives notice under Section 708A(5) of the Corporations Act that:

- (a) The Company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
  - a. Chapter 2M of the Corporations Act as they apply to the Company; and
  - b. Section 674 of the Corporations Act; and
- (c) as at the date of this notice there is no information
  - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
    - ii. the rights and liabilities attaching to the relevant securities

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

ENDS

ASX release authorised by Chief Operating Officer and Joint Company Secretary.

For further information, please contact:



**Steven Xu**  
Executive Chairman  
e: [corporate@epsilonhc.com](mailto:corporate@epsilonhc.com)

**Sonny Didugu**  
Group Chief Operating Officer  
e: [coo@epsilonhc.com](mailto:coo@epsilonhc.com)

**Epsilon Healthcare Limited (ASX: EPN) – [epsilonhealthcare.com.au](http://epsilonhealthcare.com.au)**

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport Facility) and the Tetra Health clinic group. EPN has a strategic partnership with The Valens Company (NASDAQ: VLNS), a leading cannabis consumer products company with significant expertise in manufacturing cannabinoid based products, for operation and management of its Southport Facility.